Pregnancy: Contraindicated in pregnancy.
Lactation: Contraindicated or not recommended.
Precautions: Risk of arthropathy in children and adolescents; evaluate risk/benefit ratio before treatment initiation. History of tendon disorder. Epilepsy, history to CNS disorder. Renal impairment. Crystalluria; patients should be well hydrated. G6PD deficiency. Risk factors for QT prolongation. Avoid prolonged exposure to UV. Driving or operating machinery. Myasthenia gravis. Elderly.
Gram-negative lower respiratory tract, skin and soft tissue infections. GI, intra-abdominal bone and joint infections. UTI, chronic suppurative otitis media, sinusitis, gonococcal urethritis and cervicitis, epididymo-orchitis, pelvic Inflammatory disease, malignant external otitis. Treatment and prophylaxis of infection in neutropenic patients Prophylaxis of invasive infections due to N. meningitis. Inhalation anthrax. Broncho-pulmonary infections in cystic fibrosis caused by P. aeruginosa in children.
ORAL: Adults: 250-750 mg bid usually for 1-2 weeks depending on severity and response. Lower RTI: Mild-Moderate: 500 mg bid x 1-2 weeks. Severe: 750 mg bid or 500 mg tid x 1-2 weeks.
Bone Infection: Mild-Moderate: 500 mg bid x 4-6 weeks. Severe: 750 mg bid x 4-6 weeks.
Skin Infection: Mild-Moderate: 500 mg bid x 1-2 weeks. Severe: 750 mg bid x 1-2 weeks.
UTI: Acute Uncomplicated: 100 mg or 250 mg bid x 3 days. Mild/Moderate: 250 mg bid x 1-2 weeks. Severe/Complicated: 500 mg bid x 1-2 weeks.
Acute uncomplicated cystitis: 250-500 mg bid x 3 days.
Gonorrhoea, Inhalation anthrax: 500 mg bid x 60 days after confirmed or suspected exposure.
Children: Used on
IV: Administer by slow IV infusion over 60 min into a large vein to reduce the risk of venous irritation (burning, pain, erythema, and swelling); final concentration for administration should not exceed 2 mg/mL.
Reconstitution: Injection, vial: May be diluted with NS, D5W, SWFI, D10W, D5¼NS, D5½ NS, LR.
Compatibility: Stable in D5¼NS, D5½NS, D5W, D10W, LR, NS.
Phenytoin, cyclosporin, oral anticoagulants, NSAIDs, glibenclamide, tizanidine, ropinirole, other CYP1A2 substrates, opiates, probenecid, metoclopramide, corticosteroids, methotrexate, magnesium, aluminium, calcium or iron salts, sevelamer, sucralfate, duloxetine, clozapine, theophylline and other xanthine derivatives. Drugs that inhibit peristalsis.
Nausea, diarrhoea, rash. Hypersensitivity/skin reactions; discontinue if occur. Very rarely, tendon inflammation and rupture, pseudomembranous colitis; discontinue if tendinitis or persistent diarrhoea develops. Injection: Local reaction.